Clinical Trial

Organoid Models of Hepatocellular Carcinoma

Recruiting
View on ClinicalTrials.gov →
Summary
A promising tool to elucidate the molecular characteristics of HCC are patient-derived organoids (PDOs), three-dimensional cultures of cells that self-organise according to tissue-specific patterns and can be used to test the susceptibility of a specific tumour to anticancer agents. In this study, PDOs for HCC will be developed that closely resemble the tumour microenvironment in vivo and mimic the crosstalk of the gut-liver axis to establish a correlation with patient prognosis and test the efficacy of available systemic therapies.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-15; most recent amendment 2026-05-18.
Trial Details
NCT Number NCT06929845
Lead Sponsor Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Conditions Hepatocellular Carcinoma, Organoids, Gut Microbiota, Tumor Microenvironment, System Disorders, Digestive, Surgery
Enrollment 150 participants
Start Date 2024-10-01
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-19